Novartis leukemia drug gets FDA priority review for potential leukemia treatment Tasigna

We recommend: buy doxycycline canada, buy glucophage canada, buy keflex canada

NEW YORK — Novartis AG aforementioned Friday its leucaemia dose prospect Tasigna standard antecedence follow-up by the Food and Drug Administration.

The limited appellative speeds up the regulative reassessment outgrowth to six months from the common 10 months.

Novartis, based in Switzerland, likewise makes the cancer dose Gleevec.

(This adaptation CORRECTS the floor to notation that Novartis makes Gleevec.)

Filed nether Cancer , FDA , News | Tags: Diagnosis And Treatment , Diseases And Conditions , Geography , Medication , New York , North America , United States | Comment Below

Today besellers: buy levaquin canada, buy lexapro canada, buy neurontin canada

Tags:

Leave a Reply

Categories
Search